Chrysalis Biotherapeutics, Inc.
Dba Chrysalis Biotherapeutics Inc
CAGE Code: 5DAY4
NCAGE Code: 5DAY4
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 829971899
Summary
Chrysalis Biotherapeutics, Inc., Dba Chrysalis Biotherapeutics Inc is an Active Commercial Supplier with the Cage Code 5DAY4 and is tracked by Dun & Bradstreet under DUNS Number 829971899..
Address
2200 Market St
Ste 604
Galveston TX 77550-1532
United States
Points of Contact
- Telephone:
- 2813525247
Related Information
People who viewed this 'CAGE Code' also viewed...
Juarez Victor M City Of Galveston Police Department Galtex Pilots Service Corp Kennedy Con Inc Ocean Runner Incorporated Roger Freeman Phoenix Utility Products Corporation Associate Professional Engineering J-Broker Mbp Corp. Evergreen Helicopters Inc Galveston Island Exterminating Galveston Historical Foundation, Inc O'connell High School Foundation American National Insurance Company R H John Chart Agency Inc Texas Restoration & Recovery Center Leroy G. Hoskins Llc Auzston Walter D. Crc International Archeology &
Frequently Asked Questions (FAQ) for CAGE 5DAY4
- What is CAGE Code 5DAY4?
- 5DAY4 is the unique identifier used by NATO Organizations to reference the physical entity known as Chrysalis Biotherapeutics, Inc. Dba Chrysalis Biotherapeutics Inc located at 2200 Market St, Ste 604, Galveston TX 77550-1532, United States.
- Who is CAGE Code 5DAY4?
- 5DAY4 refers to Chrysalis Biotherapeutics, Inc. Dba Chrysalis Biotherapeutics Inc located at 2200 Market St, Ste 604, Galveston TX 77550-1532, United States.
- Where is CAGE Code 5DAY4 Located?
- CAGE Code 5DAY4 is located in Galveston, TX, USA.
Contracting History for CAGE 5DAY4 Most Recent 25 Records
- 75A50119C00016
- Chrysalis Biotherapeutics - Revise Sow Option 18 And Add Supplemental Funding.
- 9 Jun 2022
- Chrysalis Biotherapeutics - Revise Sow Option 18 And Add Supplemental Funding.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $24,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Chrysalis Biotherapeutics - Advance The Development Of Tp508
- 31 Oct 2021
- Chrysalis Biotherapeutics - Advance The Development Of Tp508
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $21,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- 24 Nov 2020
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $21,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Chrysalis Biotherapeutics - Revise Sow Option 3 And Add Hhsar Clause 352.232-71, Electronic Submission Of Payment Requests.
- 9 May 2022
- Chrysalis Biotherapeutics - Revise Sow Option 3 And Add Hhsar Clause 352.232-71, Electronic Submission Of Payment Requests.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $21,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Chrysalis Biotherapeutics - No Cost Extension For Clin 0015 Option 14.
- 18 Jan 2023
- Chrysalis Biotherapeutics - No Cost Extension For Clin 0015 Option 14.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $24,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- 7 Apr 2021
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $21,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Chrysalis Biotherapeutics - No Cost Extension For Clin 0001 Base Period.
- 9 Nov 2022
- Chrysalis Biotherapeutics - No Cost Extension For Clin 0001 Base Period.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $24,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Chrysalis Biotherapeutics - Advance The Development Of Tp508
- 30 Jul 2021
- Chrysalis Biotherapeutics - Advance The Development Of Tp508
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $21,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Chrysalis Biotherapeutics - No Cost Extension - Clin 0009 Option 8.
- 14 Sep 2022
- Chrysalis Biotherapeutics - No Cost Extension - Clin 0009 Option 8.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $24,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Chrysalis Biotherapeutics - No Cost Extension For Clin 0004 Option 3.
- 5 Dec 2022
- Chrysalis Biotherapeutics - No Cost Extension For Clin 0004 Option 3.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $24,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- 4 Dec 2019
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $11,432,848.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- 1 Jul 2019
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $10,074,093.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- 16 Mar 2021
- Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of Tp508. To Achieve This Objective, We Will Conduct Non-Clinical Efficacy Survival Studies In Male And Female Minipigs With
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $21,888,229.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00016
- Eo14042 Chrysalis Biotherapeutics - Advance The Development Of Tp508
- 29 Oct 2021
- Eo14042 Chrysalis Biotherapeutics - Advance The Development Of Tp508
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $21,888,229.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- A Novel Nuclear Countermeasure Targeting Endothelial Cells And Stem Cellsto Combat Ars And Delayed Multiple Organ Dysfunction
- 26 Mar 2021
- A Novel Nuclear Countermeasure Targeting Endothelial Cells And Stem Cellsto Combat Ars And Delayed Multiple Organ Dysfunction
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,954,509.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- Revise Article B.3. Advance Understandings, Subcontract
- 5 Mar 2019
- Revise Article B.3. Advance Understandings, Subcontract
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,454,357.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- A Novel Nuclear Countermeasure Targeting Endothelial Cells And Stem Cellsto Combat Ars And Delayed Multiple Organ Dysfunction
- 22 Sep 2020
- A Novel Nuclear Countermeasure Targeting Endothelial Cells And Stem Cellsto Combat Ars And Delayed Multiple Organ Dysfunction
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,954,509.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- Supplemental Work - Sars-Cov-2 Preclinical Work
- 10 Aug 2020
- Supplemental Work - Sars-Cov-2 Preclinical Work
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,954,509.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- To Modify Articles B.2. And I.3.
- 27 Sep 2019
- To Modify Articles B.2. And I.3.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,454,357.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- To 1) Revise Article B.3., Advance Understandings, Subparagraph A., Subcontracts, And 2) Update Article C.2. Reporting Requirements.
- 22 Oct 2018
- To 1) Revise Article B.3., Advance Understandings, Subparagraph A., Subcontracts, And 2) Update Article C.2. Reporting Requirements.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,589,459.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- A Novel Nuclear Countermeasure Targeting Endothelial Cells And Stem Cellsto Combat Ars And Delayed Multiple Organ Dysfunction
- 2 Mar 2021
- A Novel Nuclear Countermeasure Targeting Endothelial Cells And Stem Cellsto Combat Ars And Delayed Multiple Organ Dysfunction
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,954,509.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- Supplemental Work-Sars-Cov-2 Option - Aim 5
- 28 Jul 2020
- Supplemental Work-Sars-Cov-2 Option - Aim 5
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,954,509.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- Deobligate Funds From Line Item.
- 5 Apr 2023
- Deobligate Funds From Line Item.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,954,508.60
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- To Modify Article B.2. And Article F.1.
- 17 Dec 2019
- To Modify Article B.2. And Article F.1.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,454,357.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700011C
- Igf::Ot::Igf Tp508: Exercise Option 2 Period: Assess The Effect Of Tp508
- 15 Jan 2019
- Igf::Ot::Igf Tp508: Exercise Option 2 Period: Assess The Effect Of Tp508
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,454,357.00
- Department Of Health And Human Services (Hhs)